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Dear editor
We thank Dr Curtis for his interest in our article,1 and welcome the opportunity to 
address the putative role of molds and fungi in chronic rhinosinusitis (CRS).
The potential contribution of fungi to the pathophysiology of CRS has been a focus of 
investigation many years back, and showed strong variation depending on the environ-
ment and climate.2,3 The emerging understanding that the nose and sinuses naturally host 
a microbiome including viruses, bacteria, and fungi, suggests that the presence of 
microorganisms is itself not a key etiological factor in CRS.4 Moreover, there is a lack 
of convincing immunological data to link fungi to the disease process in the great 
majority of CRS cases.5 Consistent with this understanding, a 2018 Cochrane Review 
found no good evidence that oral or topical antifungals have a positive effect of quality of 
life, symptoms, or signs of disease in patients with CRS.6 Indeed, consensus guidelines 
advise against the use of antifungals in CRS.4
Among the phenotypes of CRS, allergic fungal rhinosinusitis (AFRS) is recognized 
as distinct from CRS with nasal polyps (CRSwNP), which was the subject of our review, 
in its diagnosis, presentation, clinical course, pathophysiology, and management.4,7,8 
AFRS is a chronic disease that occurs predominantly in warm, humid climates and is 
characterized by a robust type 2 inflammatory response directed against colonizing fungi 
with accumulation of eosinophilic mucin containing fungal hyphae leading to persistent 
sinus opacification and nasal polyp formation. However, there is good evidence that 
AFRS accounts for only approximately 5–10% of CRS cases.4,9–12 The study referenced 
in Dr Curtis’ letter, which reported presence of AFRS in 94 of 101 CRS surgical patients, 
investigated a heterogenous population of patients with CRSwNP as well as CRS without 
nasal polyps diagnosed by recurrent upper tract infections lasting longer than 3 months 
and inflammatory mucosal thickening,13 which is not consistent with the current diag-
nostic criteria for CRSwNP,4 and reported a large heterogeneity in polyp size from 
“minimal” to “massive”. The contribution of fungi to CRS in this study is particularly 
unclear since 100% of the control population were reported as culture-positive for fungi, 
with a microbiome profile similar to that of CRS patients.
While the potential association between CRS, including AFRS, and exposure to mold 
is an area of investigation, a causal relationship has never been demonstrated. A reduction 
in rhinosinusitis symptoms following reduction in allergen exposure is not surprising in 
patients with CRS and allergic rhinitis. However, a recent analysis of home mold 
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exposure found no difference in exposure levels between 
patients with AFRS and controls with atopic CRSwNP, 
which suggests that mold exposure levels may not be a key 
driver in development of AFRS.14
In summary, the absence of convincing evidence after 
more than two decades of investigation suggests that the 
hypothesis of fungi playing a major role in the pathophy-
siology of CRS in general has not been accepted; future 
research may identify genetic traits, or its interplay with 
environmental factors in CRSwNP disease evolution.
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